Skip to content

Real world study on the treatment of ischemic stroke with Pushen capsules

Real world study on the treatment of ischemic stroke with Pushen capsules

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000255
Enrollment
Unknown
Registered
2025-02-13
Start date
2024-10-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Disease Registry Group:not have
Pushen Capsules Group:4 capsules/time 3 times/day

Sponsors

Drum Tower Hospital Affiliated to Nanjing University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients admitted to the hospital who were diagnosed as ischemic stroke (in line with the diagnostic criteria for ischemic stroke in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018) and those who met the TOAST were diagnosed as Large artery atherosclerosis (LAA); (2) Patients who have been ill for less than 7 days; (3) Patients give informed consent to the study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) History of cerebral hemorrhage or hemorrhagic cerebrovascular disease (diagnosed by head CT/MRI including subarachnoid hemorrhage cerebral hemorrhage and other intracranial hemorrhage) within the past six months; (2) Confirmed through examination that cerebral embolism is caused by brain tumors traumatic brain injury cerebral parasitic diseases metabolic disorders rheumatic heart disease coronary heart disease and other heart diseases combined with atrial fibrillation and thrombus detachment as well as patients of unknown etiology; (3) Diabetes complications (such as severe diabetes nephropathy leading to renal insufficiency diabetes peripheral neuropathy affecting patients' motor function evaluation diabetes ketoacidosis etc.) and recurrent hypoglycemia; (4) Patients with severe malnutrition and severe blood diseases (such as hypoalbuminemia severe anemia etc.) and severe electrolyte imbalances that cannot be corrected through treatment; (5) Patients with severe cardiovascular and pulmonary diseases as w

Design outcomes

Primary

MeasureTime frame
The proportion of subjects with mRS scores ranging from 0 to 2 after 12 weeks of treatment.;

Secondary

MeasureTime frame
Has the mRS score decreased to 0-1 points;The change value and rate of NIHSS score;Whether cardiovascular and cerebrovascular events occur (stroke myocardial infarction TIA death etc.);The change value and rate of change in the Montreal Cognitive Assessment Scale (MoCA) score;The change value and rate of TCM symptom score;mRS score improvement rate;The change value and rate of the Mini Mental State Examination (MMSE) score;Changes in Four Blood Lipids;

Countries

China

Contacts

Public ContactXu Yun

Nanjing Gulou Hospital

xuyun20042001@aliyun.com+86 13914764479

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026